Načítá se...
T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity
Focal Adhesion Kinase (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune checkpoint inhibitors. However, which patients are most likely to benefit from FAK inhibitors, and what the optimal FAK/immunotherapy combinations are, is currently unknown. We ident...
Uloženo v:
| Vydáno v: | eLife |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
eLife Sciences Publications, Ltd
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6974352/ https://ncbi.nlm.nih.gov/pubmed/31959281 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.48092 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|